| Company Name: |
Alfa Aesar |
| Tel: |
400-6106006 |
| Email: |
saleschina@alfa-asia.com |
|
| | (R)-N-Boc-3-aminomethylpiperidine Basic information | | Synthesis Uses |
| | (R)-N-Boc-3-aminomethylpiperidine Chemical Properties |
| Boiling point | 299.4±13.0 °C(Predicted) | | density | 0.997g/mLat 25℃ | | refractive index | n20/D 1.473 | | Fp | >110°C | | storage temp. | 2-8°C | | pka | 10.12±0.29(Predicted) | | form | Liquid | | color | Clear colorless to pale yellow | | InChI | 1S/C11H22N2O2/c1-11(2,3)15-10(14)13-6-4-5-9(7-12)8-13/h9H,4-8,12H2,1-3H3/t9-/m1/s1 | | InChIKey | WPWXYQIMXTUMJB-SECBINFHSA-N | | SMILES | CC(C)(C)OC(=O)N1CCC[C@H](CN)C1 | | CAS DataBase Reference | 140645-23-4(CAS DataBase Reference) |
| Hazard Codes | Xi,Xn,N | | Risk Statements | 22-50-36/37/38 | | Safety Statements | 26-61 | | RIDADR | UN 3082 9 / PGIII | | WGK Germany | 3 | | HS Code | 2933399990 | | Storage Class | 10 - Combustible liquids | | Hazard Classifications | Acute Tox. 4 Oral
Aquatic Acute 1
Eye Irrit. 2
Skin Irrit. 2
STOT SE 3 |
| | (R)-N-Boc-3-aminomethylpiperidine Usage And Synthesis |
| Synthesis | Using 3-piperidineacetic acid as a starting material, the important pharmaceutical intermediate 1-Boc-3-aminomethylpiperidine was synthesized in a five-step reaction involving esterification, reduction, tert-butyloxycarbonyl protection, bromination, and methylamination, with an overall yield of 72%. (R)-N-Boc-3-aminomethylpiperidine was then prepared by chiral resolution. The synthetic route is shown below: 
Figure 1 Synthetic route of (R)-N-Boc-3-aminomethylpiperidine | | Uses | (R)-1-Boc-3-aminomethylpiperidine is an important intermediate in the synthesis of many drugs. A series of checkpoint kinase 1 (CHK1) inhibitors have been synthesized using (R)-1-Boc-3-aminomethylpiperidine as a starting material, showing some efficacy in treating rheumatoid arthritis. A series of drugs for treating diseases related to MCH (melanin-concentrating hormone) have also been synthesized using this compound, showing some effectiveness in treating metabolic disorders. G-protein-coupled receptor (GPCR) agonists containing the 1-N-Boc-4-methylaminomethylpiperidine structural unit have been synthesized, which can be used to treat obesity and diabetes. A series of drugs for regulating metabolism and treating cardiovascular diseases have also been synthesized using (R)-1-Boc-3-aminomethylpiperidine. |
| | (R)-N-Boc-3-aminomethylpiperidine Preparation Products And Raw materials |
|